Our Pipeline
comes from our unique approach
All of our programs are first-in-class and internally generated, each representing an opportunity that can treat numerous diseases.
IMMUNOLOGY
ELA026
Myeloid and T cell depletor
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Additional Indications
UNDISCLOSED MOA
Autoimmune Diseases
IMMUNO-ONCOLOGY
UNDISCLOSED MOA
Various Cancers
IND=investigational new drug.
MOA=mechanism of action.
POC=proof-of-concept.
